May 1st 2024
The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Survival Benefit Shown With IA Gemcitabine in Patients with Locally Advanced Pancreatic Cancer
July 10th 2023In the phase 3 TIGeR-PaC study, intra-arterial administration of gemcitabine demonstrated positive progression-free and overall survival outcomes in patients with locally advanced pancreatic cancer.
Read More
Li Assesses Evolving Therapies in Biliary Tract Cancers
July 7th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, and participants discussed current approaches to treating biliary tract cancers, including the TOPAZ-1 study regimen of cisplatin, gemcitabine, and durvalumab.
Read More
FDA Grants Priority Review to BLA for Zolbetuximab in Advanced, HER2-, CLDN18.2+ Gastric/GEJ Cancer
July 6th 2023The FDA plans to conduct a speedy review of an approval application for zolbetuximab in first-line locally advanced, unresectable, or metastatic HER2-negative, claudin18.2-positive gastric or gastroesophageal junction adenocarcinoma.
Read More
Neoadjuvant Pembrolizumab Plus Chemotherapy Shows Significant Efficacy in GEJ Cancer
June 20th 2023According to phase 3 study results, the combination of pembrolizumab and chemotherapy can induce high rates of response in patients with gastroesophageal junction adenocarcinoma while maintaining safety.
Read More
FDA Grants Orphan Drug Designation to Mitazalimab for Pancreatic Cancer
May 23rd 2023Mitazalimab has received an orphan drug designation from the FDA and is currently being investigated in the OPTIMIZE-1 trial in combination with modified FOLFIRINOX for the treatment of patients with pancreatic cancer.
Read More
FDA Grants Orphan Drug Designation to Rucosopasem for Pancreatic Cancer
May 19th 2023Rucosopasem manganese is being investigated in the phase 1/2 GRECO-1 and phase 2b GRECO-2 trials in combination with stereotactic body radiation therapy for the treatment of patients withlj non–small cell lung cancer and pancreatic cancer.
Read More
Nivolumab Combinations Improve Survival But Are Not Cost-Prohibitive in Advanced ESCC
May 9th 2023An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.
Read More
Emerging Approaches for Gastric/GEJ Cancers Take the Spotlight at ASCO GI
May 9th 2023Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.
Read More
FDA Grants Fast Track Designation to Botensilimab/Balstilimab for MSS/dMMR mCRC Treatment
April 18th 2023The combination of botensilimab and balstilimab is moving down the FDA pipeline and may become an approved treatment for non-microsatellite instability-high and deficient mismatch repair metastatic colorectal cancer in the future.
Read More
Esophageal Cancer Awareness Month: Paradigm Shifts in Targetable Disease
April 17th 2023In an interview with Targeted Oncology for Esophageal Cancer Awareness Month, Arturo Loaiza-Bonilla, MD, MSEd, discussed the pressing need to keep up with the developments in targeted therapies for esophageal and GEJ cancers.
Read More